Vertex Appoints Lloyd Carney to its Board of Directors
February 21 2019 - 4:01PM
Business Wire
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today
announced that Lloyd Carney has been appointed to its board of
directors as an independent director. Mr. Carney is a prominent
technology executive with experience leading innovative,
high-growth organizations. He currently serves as the Chairman and
Chief Executive Officer of ChaSerg Technology Acquisition Corp., a
technology acquisition company. The addition of Mr. Carney brings
Vertex’s board of directors to 10 members.
“We are thrilled to have Lloyd join the Vertex Board. His wealth
of leadership and management experience paired with his passion for
technology and innovation bring an invaluable perspective to the
Vertex leadership team,” said Jeffrey Leiden, M.D., Ph.D.,
Chairman, President and Chief Executive Officer of Vertex.
“It’s an honor to join an organization with a strong track
record of discovering new medicines to treat life-threatening
diseases like cystic fibrosis,” said Lloyd Carney. “I look forward
to working with my fellow board members to support Vertex in its
continued efforts to serially innovate for the benefit of people
with serious diseases.”
Prior to his role at ChaSerg, Mr. Carney served as Chief
Executive Officer of Brocade Communications Systems, a global
supplier of networking hardware and software, until its acquisition
by Broadcom in 2017. Previously, Mr. Carney served as Chief
Executive Officer of Xsigo Systems, a cloud-based infrastructure
solutions provider, until its acquisition by Oracle. He has also
served as the Chief Executive Officer and Chairman of Micromuse
Inc., a software solutions provider for business and service
assurance. Earlier in his career he held senior leadership roles at
Juniper Networks Inc., Nortel Networks Inc., and Bay Networks Inc.
Mr. Carney currently serves as an independent director of Visa Inc.
and the chairman of the board of Nuance Communications Inc.
Mr. Carney holds a Bachelor of Science degree in electrical
engineering technology from Wentworth Institute, a Master of
Science degree in applied business management from Lesley College,
and an honorary doctorate degree in engineering from Wentworth
Institute.
About Vertex
Vertex is a global biotechnology company that invests in
scientific innovation to create transformative medicines for people
with serious and life-threatening diseases. In addition to clinical
development programs in CF, Vertex has more than a dozen ongoing
research programs focused on the underlying mechanisms of other
serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex's headquarters is
now located in Boston's Innovation District. Today, the company has
research and development sites and commercial offices in the United
States, Europe, Canada, Australia and Latin America. Vertex is
consistently recognized as one of the industry's top places to
work, including being named to Science magazine's Top Employers in
the life sciences ranking for nine years in a row.
For additional information and the latest updates from the
company, please visit www.vrtx.com.
(VRTX-GEN)
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190221005847/en/
Vertex Pharmaceuticals
IncorporatedInvestors:Michael Partridge,
617-341-6108orEric Rojas, 617-961-7205orZach Barber,
617-341-6470orMedia:mediainfo@vrtx.comorNorth America: +1
617-341-6992
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024